Naslov
Intensified Dosing of Mycophenolate Mofetil Is Associated with Slower Progression of Chronic Renal Allograft Injury – Results from a Randomized Controlled Trial

Autori
Knotek, Mladen ; Arnol, Miha ; Buturovic-Ponikvar, Jadranka ; Galešic Ljubanović, Danica ; Kojc, Nika

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Journal of the American Society of Nephrology / - , 2015

Skup
American Society of Nephrology Kidney Week

Mjesto i datum
San Diego (CA), Sjedinjene Američke Države, 03.11.2015. - 08.11.2015

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Mycophenolate mofetil; chronic renal allograft injury

Sažetak
Background: Interstitial fibrosis (ci) is a major histological predictor of long-term graft outcome. This randomized controlled trial (NCT01860183) was designed to evaluate the effect of intensified mycophenolate mofetil (MMF) dosing on progression of ci during the first year post kidney transplant (KT). Methods: Immunologically low-risk KT recipients were randomized on MMF 3g/d, or 2g/d during the first year post KT. Immunosuppression consisted of basiliximab induction, with tacrolimus, MMF ± steroids. Protocol biopsies were performed at implantation, and at 12 months post KT and were scored according to the Banff. Progression of ci (Δci) was calculated as ci12-ci0. MMF dose was calculated as an average dose at 1, 3, 6 and 12 months. Difference in Δci with respect to MMF dose was analyzed in an ITT population using one- way ANOVA. Results: Here we report interim results from patients who completed 12 month follow-up by June 1st 2015. Patient and KT data are were similar in MMF 3g and MMF 2g group, except for average MMF dose, which was higher in the 3g group (2697.1±321.6 vs. 1745.5±359.0 g, p<0.001). In an overall study population ci progressed during first 12 months post KT from 0.45±0.51 (ci0) to 1.41±0.87 (ci12) (p<0.001). Δci was lower in the MMF 3 g group (0.60±0.74) as compared with MMF 2g group (1.36±0.93 ; p=0.021). Serum creatinine at 1 year was similar in both MMF groups (116.5±25.0 vs. 115.1±33.7 ; p=0.899). Incidence of acute rejection was similar and no significant differences were seen in common adverse events between both groups. Conclusions: Intensified dosing of MMF (3g daily) during the first posttransplant year in a tacrolimus-based regimen may be associated with slower progression of chronic allograft injury.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA